DPYD genotype testing can help individualize fluoropyrimidine therapy for cancer patients and reduce the risk of severe toxicity. A recent safety analysis found that implementation of DPYD genotype testing should be the new standard of care. Carolina Diagnostic Labs LLC offers Test ID DYPD from our offered Open array chip based PGX assay, can identify biallelic variations in the DPYD gene associated with drug sensitivity and dihydropyrimidine dehydrogenase deficiency. Patients with variations in the DPYD gene may benefit from genetic consultation. Let’s work towards more personalized and safer cancer treatment options. #pharmacogenomics #cancertreatment #DPYDgenotyping #teamcarolinadx
